135 related articles for article (PubMed ID: 37818552)
1. The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.
Kaya M; Girişgen İ; Yalçın N; Becerir T; Şenol H; Gülten G; Yüksel S
Fetal Pediatr Pathol; 2023 Dec; 42(6):936-949. PubMed ID: 37818552
[TBL] [Abstract][Full Text] [Related]
2. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
Watanabe S; Hirono K; Aizawa T; Tsugawa K; Joh K; Imaizumi T; Tanaka H
Clin Exp Nephrol; 2021 Jan; 25(1):44-51. PubMed ID: 32946006
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Watanabe S; Tsugawa K; Tsuruga K; Imaizumi T; Tanaka H
Pediatr Int; 2017 Oct; 59(10):1112-1115. PubMed ID: 29081073
[TBL] [Abstract][Full Text] [Related]
4. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
5. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Ravani P; Ponticelli A; Siciliano C; Fornoni A; Magnasco A; Sica F; Bodria M; Caridi G; Wei C; Belingheri M; Ghio L; Merscher-Gomez S; Edefonti A; Pasini A; Montini G; Murtas C; Wang X; Muruve D; Vaglio A; Martorana D; Pani A; Scolari F; Reiser J; Ghiggeri GM
Kidney Int; 2013 Nov; 84(5):1025-33. PubMed ID: 23739238
[TBL] [Abstract][Full Text] [Related]
6. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
Takahashi Y; Ikezumi Y; Saitoh A
Nephrology (Carlton); 2017 Jan; 22(1):49-57. PubMed ID: 26833819
[TBL] [Abstract][Full Text] [Related]
7. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.
Tasaki M; Shimizu A; Hanekamp I; Torabi R; Villani V; Yamada K
J Am Soc Nephrol; 2014 Apr; 25(4):737-44. PubMed ID: 24459229
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Rituximab in Children With Steroid- and Cyclosporine-resistant and Steroid- and Cyclosporine-dependent Nephrotic Syndrome.
Hoseini R; Sabzian K; Otukesh H; Zafaranloo N; Panahi P; Rahimzadeh N; Nakhaie S; Akhavan Sepehi M
Iran J Kidney Dis; 2018 Jan; 12(1):27-32. PubMed ID: 29421774
[TBL] [Abstract][Full Text] [Related]
9. Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.
Watanabe S; Hidenori U; Hashimoto S; Riko S; Aizawa T; Tsugawa K; Imaizumi T; Tanaka H
J Membr Biol; 2022 Feb; 255(1):117-122. PubMed ID: 34739556
[TBL] [Abstract][Full Text] [Related]
10. Rituximab treatment for difficult-to-treat nephrotic syndrome in children: a multicenter, retrospective study.
Taşdemir M; Canpolat N; Yıldız N; Özçelik G; Benzer M; Saygılı SK; Özkayin EN; Türkkan ÖN; Balat A; Candan C; Çelakıl M; Yavuz S; Akıncı N; Göknar N; Akgün C; Tülpar S; Alpay H; Sever FL; Bilge İ
Turk J Med Sci; 2021 Aug; 51(4):1781-1790. PubMed ID: 33581711
[TBL] [Abstract][Full Text] [Related]
11. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu ID; Willis NS; Craig JC; Hodson EM
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab.
Kamei K; Ishikura K; Sako M; Aya K; Tanaka R; Nozu K; Kaito H; Nakanishi K; Ohtomo Y; Miura K; Takahashi S; Morimoto T; Kubota W; Ito S; Nakamura H; Iijima K;
Pediatr Nephrol; 2017 Nov; 32(11):2071-2078. PubMed ID: 28664242
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis.
Nagai K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984602
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in the treatment of nephrotic syndrome: a systematic review.
Otukesh H; Hoseini R; Rahimzadeh N; Fazel M
Iran J Kidney Dis; 2013 Jul; 7(4):249-56. PubMed ID: 23880800
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nephrotic syndrome: going beyond immunosuppressive therapy.
Zhao J; Liu Z
Pediatr Nephrol; 2020 Apr; 35(4):569-579. PubMed ID: 30904930
[TBL] [Abstract][Full Text] [Related]
16. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
Kemper MJ; Valentin L; van Husen M
Pediatr Nephrol; 2018 Oct; 33(10):1641-1649. PubMed ID: 28879428
[TBL] [Abstract][Full Text] [Related]
17. Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children.
Kamei K; Ishikura K; Sako M; Ito S; Nozu K; Iijima K
Pediatr Nephrol; 2020 Jan; 35(1):17-24. PubMed ID: 30564879
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.
Trautmann A; Bodria M; Ozaltin F; Gheisari A; Melk A; Azocar M; Anarat A; Caliskan S; Emma F; Gellermann J; Oh J; Baskin E; Ksiazek J; Remuzzi G; Erdogan O; Akman S; Dusek J; Davitaia T; Özkaya O; Papachristou F; Firszt-Adamczyk A; Urasinski T; Testa S; Krmar RT; Hyla-Klekot L; Pasini A; Özcakar ZB; Sallay P; Cakar N; Galanti M; Terzic J; Aoun B; Caldas Afonso A; Szymanik-Grzelak H; Lipska BS; Schnaidt S; Schaefer F;
Clin J Am Soc Nephrol; 2015 Apr; 10(4):592-600. PubMed ID: 25635037
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
